• Synthesize Bio

  Participated · Seed · Sep 2025

  Synthesize Bio is a biotechnology startup developing biological foundation models capable of predicting the results of gene-expression experiments with high fidelity. Its inaugural Generate Expression Model-1 (GEM-1) was trained on one of the most deeply curated RNA-seq datasets assembled and can generate in-silico data directly from experimental design descriptions, including experiments that are currently infeasible in the lab. By augmenting or replacing wet-lab work, GEM-1 aims to help biopharma partners identify drug targets, assess safety and efficacy, and optimize clinical-trial design more quickly and cost-effectively. The company is actively engaging with pharmaceutical companies to integrate its models across the R&D pipeline and offers access to GEM-1 through web, R, and Python APIs. Founded by Fred Hutchinson Cancer Center scientists Rob Bradley, PhD, and Jeff Leek, PhD, the Seattle-based venture positions itself at the intersection of AI and life sciences. The recently raised seed capital finances model enhancement and broader commercial access; no revenue or user metrics were disclosed.

• Apkudo

  Participated · Series C · Feb 2023

  Apkudo provides a platform for companies to manage, sell and test connected devices such as smartphones, tablets, laptops and wearables, handling grading, pricing and both in-lab and field testing. The platform uses AI to predict where devices are likely to be lost or stolen and to distinguish cosmetic issues (smudges, scratches, chips, cracks) to assess condition. Apkudo’s customers include FedEx, T-Mobile and Asurion, and its customer base grew 30% year-over-year from last February. The company says it was built capital-efficiently by solving for sophisticated buyers and aims to expand beyond mobility into compute. Apkudo has about 180 employees and disclosed that its annual recurring revenue grew around 141% year over year; no raw revenue figures were provided. Management plans to use the new capital to expand engineering teams, build out go-to-market functions and establish a physical presence outside the U.S. Apkudo provides a connected device platform that connects internal systems and ecosystem partners to automate supply chain processes across the full device lifecycle. Its platform surfaces condition and value data to drive inventory management, reverse logistics, repair, resale and recycling decisions. Apkudo has expanded beyond wireless mobility to serve computer and laptop brands and integrates with partners such as FedEx Supply Chain Robotics and ERI. The company says it has tripled the number of customers on its platform over the past two years. Apkudo positions its technology to strengthen circular supply chains and reduce e-waste by improving refurbishment and recycling outcomes. The company will use new funding to accelerate growth and advance development of its connected device platform. Apkudo provides a universal system for managing connected devices across the entire supply chain by securely bridging internal systems and external partners into a single platform. Its Hive Device Platform leverages AI-enhanced test software and high-volume robotics for diagnostics and cosmetic grading to drive supply chain efficiencies. Customers include smartphone manufacturers such as Samsung and LG, carriers including AT&T Mexico, T-Mobile and Verizon, and marketplaces like Amazon. The company plans to use new funding to accelerate global expansion of the Hive platform across emerging channels and verticals. Apkudo was founded in 2011 by Josh Matthews and Ben Leslie and is based in Baltimore, MD. It recently completed a Series B raise to support these growth efforts.

• Craft.co

  Participated · Series B · Feb 2023

  Craft offers a cloud-based supplier intelligence platform that ingests internal customer systems and thousands of external sources to generate risk and opportunity insights. Its proprietary data platform produces 360-degree company profiles built from 500+ data types, refreshed with machine learning and human validation, and serves actionable insights to millions of professionals each month. Product capabilities highlighted in the past year include Craft Risk Hub, Craft N-Tier Mapping and Craft Alerts, along with expanded collaboration and case-management workflows. Customers include Fortune 500 enterprises and government agencies, and Craft reported approximately 100% revenue growth in 2022 with notable contract expansions. The company is headquartered in San Francisco and has a presence across North America and Europe. Craft plans to use new funding to deepen go-to-market execution in key verticals and accelerate research and development. Craft builds a supply chain intelligence platform consisting of a proprietary data platform, API and portal that integrates into existing enterprise workflows. Its platform is pre-deployed with data from thousands of financial and alternative sources and more than 300 data points refreshed using machine learning and human validation. Public-facing company profiles appear across the web and the platform surfaces real-time operating, human capital and risk metrics rather than only traditional financial data. The company says its product helps firms monitor and optimize supply chains and enterprise systems and aims to become the intelligence layer of the enterprise technology stack. With the new funding Craft plans to expand offices in San Francisco, London and Minsk and grow remote engineering, sales, marketing and operations teams across North America and Europe. In the first half of 2020 Craft reported revenues grew nearly threefold, with clients including Fortune 100 companies, government and military agencies, and SMEs.

• Delfi Diagnostics

  Participated · Series B · Jul 2022

  DELFI Diagnostics is a Palo Alto–based developer of blood-based cancer detection tests that use fragmentomics and advanced machine-learning methods applied to whole-genome sequencing data. The platform analyzes patterns of cell-free DNA fragments to detect chaotic signatures left by cancer cells. DELFI has commercialized FirstLook Lung, a blood test that evaluates DNA fragment patterns to indicate the presence of lung cancer. In an independent validation, FirstLook Lung demonstrated 80% sensitivity in a screening population, including early-stage detection, and a 99.8% negative predictive value. The company received an equity investment from the Merck Global Health Innovation Fund and intends to use the funds to accelerate development and commercialization of its cancer detection solutions. Led by CEO Susan Tousi, DELFI positions its fragmentomics and AI technologies as a potential high-precision, population-scale approach to early cancer detection at a disruptive price. Delfi Diagnostics has built a platform that analyzes cell-free DNA fragments across the entire genome using a proprietary, scalable whole-genome fragmentation approach. The platform is designed to enable a single, low-cost, and straightforward lab process for multiple liquid-biopsy tests and leverages machine learning to deliver high-performing results. Led by CEO and founder Victor Velculescu, the company is validating its technology for early detection of lung and other cancers in a 15,000-person prospective trial called CASCADE-LUNG. Delfi is working with multiple research institutions to develop additional applications including screening for other cancer types, multi-cancer early detection, and treatment monitoring. The company intends to use the funds raised to continue development and commercialization of single-cancer early detection, multi-cancer early detection, and treatment-monitoring blood tests. Headquarters are listed in Palo Alto, CA and Baltimore, MD. Delfi Diagnostics is a Baltimore-based company developing a new class of high-performance, affordable liquid biopsy tests for early cancer detection. Its platform leverages machine learning and genome-wide fragmentation profiles of cell-free DNA to detect evidence of tumors from a blood sample and to pinpoint tumor location. The company is applying this platform to a range of products to detect specific cancers, such as lung cancer in at-risk individuals, and to identify multiple cancers in any individual. Delfi plans to use the funding to expand its team of cancer researchers and machine learning experts and to validate its next-generation liquid biopsy technology through multiple prospective clinical studies. Financially, Delfi raised $100M in a Series A financing led by OrbiMed. The company is led by founder and CEO Victor Velculescu.

• Clear Skye

  Participated · Series A · Mar 2022

  Clear Skye offers a cloud-native identity security and governance platform built natively on ServiceNow that reimagines enterprise identity access and risk management. The product reduces silos between HR, IT, SecOps, and GRC, automates identity lifecycle and governance, and enables faster access removals and audits. Customers named in the article include ABB, West Fraser, Blackhawk Network, and Premise Health. The company reported record growth in 2021, achieving 5x revenue growth last year. Clear Skye has expanded its leadership team and plans to use new funding to grow its team, expand its global footprint, and continue developing product capabilities. The company will also publish a 'State of Identity Management' report in Q2 in partnership with research firm Gradient Flow. Clear Skye builds Identity Governance and Administration (IGA) software natively on the ServiceNow Now Platform. Its IGA delivers Identity Lifecycle Management, Provisioning, Access Request, Access Review, Access Certification and audit-focused analytics while integrating with CMDB, GRC and Security Operations. Being native to the Now Platform removes the need for another software silo and aligns identity management with existing IT workflows. The company will use the $4.95M Series A to expand all facets of the business and to accelerate international growth. Leadership changes announced alongside the round include new CEO John Milburn and worldwide leader of Sales and Alliances Luis P. Almeida, and Rajan Aggarwal of Toba Capital will join the board. Clear Skye is venture-backed and headquartered in Emeryville, Calif.

No current team members are available.